AbbVie Resolves Humira (adalimumab) Litigation with Boehringer Ingelheim

Shots:

• AbbVie has resolved the Humira litigation with BI, granting BI non-exclusive rights to BI for Humira’s IPR in the US
• BI will pay royalties for licensing HUMIRA patents and acknowledges the validity and enforceability of the licensed patents
• The initiation of the license will begin from Jul,1 2023

Click here to read full press release/ article | Ref: AbbVie| Image: Modern Healthcare